Evidence map›Paper›PMID 41076449›Full record

ArticleCancer gene therapy2025

Activating NRF2

Samera H Hamad, Hansa Joshi, T Hess, Stuart R Jefferys, Zena Saleh, Nasrine Bendjilali, Rani S Sellers, Gord Zhu, Travis Shrank, Rayvon T Moore and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Samera H HamadSurgery Department, Cooper Medical School of Rowan University, Camden, NJ, USA. hamad-samera@cooperhealth.edu.ORCID 0000-0003-4997-3324
Hansa Joshi *Surgery Department, Cooper University Health Care, Camden, NJ, USA.
T Hess *Surgery Department, Cooper University Health Care, Camden, NJ, USA.ORCID 0009-0001-3582-6756
Stuart R JefferysLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Zena SalehSurgery Department, Cooper University Health Care, Camden, NJ, USA.
Nasrine BendjilaliCollege of Science and Mathematics, Rowan University, Glassboro, NJ, USA.
Rani S SellersLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Gord ZhuSurgery Department, Cooper Medical School of Rowan University, Camden, NJ, USA.
Travis ShrankLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Rayvon T MooreLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
David CorcoranLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Jeremy M SimonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0003-3906-1663
Francis R SpitzSurgery Department, Cooper Medical School of Rowan University, Camden, NJ, USA.
David ShersherSurgery Department, Cooper Medical School of Rowan University, Camden, NJ, USA.
Michael B MajorLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0002-6753-8513
Bernard E WeissmanLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.

Funding

TOXICOLOGYT32ES007126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ILONA JASPERS, Bernard E. Weissman · 1985 to 2026
$13.0M
The Role of Protein Kinases in NRF2-driven Lung Squamous Cell CarcinomaR01CA216051 · NCI · WASHINGTON UNIVERSITY · PI MAJOR, MICHAEL BENJAMIN, WEISSMAN, BERNARD E. · 2018 to 2022
$2.5M
Drugging NRF2 to improve radiation therapy in head and neck squamous cell carcinomaR01CA290809 · NCI · WASHINGTON UNIVERSITY · PI Michael Benjamin Major, Bernard E. Weissman · 2025 to 2026
$1.3M
Identifying the effects of NRF2 signaling on lung squamous cell carcinoma developmentR21CA292297 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Benjamin Major, Bernard E. Weissman · 2025 to 2026
$413k
NCI NIH HHS R01 CA216051NCI NIH HHS R01 CA290809NCI NIH HHS R21 CA292297NIEHS NIH HHS T32 ES007126U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA216051U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) T32ES007126
6 · The paper itself

Abstract

The NRF2 signaling pathway promotes tumor initiation, progression and resistance to chemotherapy, radiation therapy and immune checkpoint inhibitors. The mechanisms underlying the biology of NRF2-active tumors are varied and include altered cellular metabolism, a reductive shift in redox state, and immunosuppression. Here we determined the molecular and phenotypic impact of NRF2 activation on two human non-small cell lung cancer (NSCLC) cell models. Inducible expression of NRF2

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationNF-E2-Related Factor 2AnimalsCell DifferentiationCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceXenograft Model Antitumor AssaysNFE2L2 protein, humanNF-E2-Related Factor 2

Identifiers

PMID41076449
PMCPMC12690292

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.